Skip to Main

The Mitophagy Company

Targeting mitochondrial biology to power therapeutic breakthroughs


Mitophagy is the evolutionarily conserved process by which dysfunctional mitochondria are tagged, removed, and replaced in cells.

Mitochondria are dynamic organelles that undergo constant cycles of fission (division of one mitochondria) and fusion (combining of two mitochondria). In a healthy cell, this process helps to segregate old, dysfunctional mitochondria from functional ones. Dysfunctional mitochondria are tagged for degradation and recycling. Engulfment of tagged mitochondria by an autophagosome and subsequent fusion with an acidic lysosome leads to activation of enzymes that break down and recycle the mitochondria. Importantly, removal of mitochondria by mitophagy triggers mitochondrial biogenesis and maintenance of the optimal mitochondrial mass specific for each cell type.

During aging or disease, the ability of the cell to identify or process dysfunctional mitochondria is deficient. The accumulation of energetically suboptimal mitochondria inside each cell leads to release of reactive oxygen species (ROS) and inflammatory signals such as cytochrome c and mtDNA, calcium dysregulation, decreased ATP production, and cell death.

While the importance of mitophagy in human health and disease is well established, strategies to safely and effectively target mitophagy remain challenging. Capacity Bio’s proprietary approach is to develop small molecules, peptides, and nanoparticles that enhance identification of dysfunctional mitochondria, activate mitophagy pathways, and promote clearance by autophagosomes and lysosomes.

Capacity Team

Ken Horne

Chief Executive Officer

Christine Maurer

Chief Operating Officer

Brian Kearney, PharmD

Chief Development Officer

Aaron Bergener

Chief Financial Officer

Shirin Arastu Kapur, PhD

Executive Director, Biomarker Development

Tanya Shnaydman

Executive Director, Program and Portfolio Management

Amy Wang, PhD

Vice President, Discovery Science

Kevin Gaffney, PhD

Vice President, Research

Karel Erion, PhD

Director of Preclinical

Susan Yen

Director of Finance

Gianpaolo Pugliares


Lada Klaic, PhD

Senior Scientist

Matheus Oliveira, PhD


Anton Petcherski, PhD


James Hungerford

Research Associate

Stan Louie, PharmD

Scientific Advisor
Professor of Clinical Pharmacy, Director of Clinical Experimental Therapeutics Program, USC

Kathleen Rodgers, PhD

Scientific Advisor
Associate Director, Translational Neuroscience, Center for Innovations in Brain Science; Professor of Pharmacology, University of Arizona

Orian Shirihai, MD, PhD

Scientific Advisor
Professor of Medicine and Molecular and Medical Pharmacology, UCLA

Board of Directors

Aiden Aceves, PhD

Board Observer
Insight Partners

Ken Horne

Board Member
Capacity Bio

Taro Inaba

Board Member
Remiges Ventures

Andrew Levin, MD, PhD

Board Member
RA Capital

Dylan Morris

Board Member
Insight Partners

Rebecca Silberman, PhD

Board Observer
RA Capital

Amy Wang, PhD

Board Member
Capacity Bio


$35M Financing to Advance Mitophagy Platform

Los Angeles, California – March 31, 2023

Capacity Bio, Inc., a mitochondria-focused biotechnology company developing novel mitophagy modulators, announced today the close of a $35 million financing round. Leading life science investor RA Capital Management and Insight Partners co-led the financing and joined existing investor Remiges Ventures to support the acceleration of Capacity Bio’s first-in-class mitophagy agonist and is expected to enter clinical trials in 2024. The financing will also advance Capacity’s preclinical programs focused on new mitochondrial modulators.